Target family: E3 ubiquitin ligase components (type: enzyme)
Target: cereblon

Ligand: AK-2292 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.770000457763672 pKi
Reference (Journal): Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity <i>In Vivo</i> in Acute Myeloid Leukemia.
Published in: J Med Chem

Ligand: avadomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.269999980926514 pIC50
Reference (Patent): Methods for the treatment of locally advanced breast cancer

Ligand: avadomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.269999980926514 pIC50
Reference (Journal): CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Published in: Blood

Ligand: CBPD-268 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.739999771118164 pIC50
Reference (Journal): Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Published in: J Med Chem

Ligand: compound 7f [PMID: 31251063] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.699999809265137 pKi
Reference (Journal): De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
Published in: J Med Chem

Ligand: compound 7f [PMID: 31251063] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.699999809265137 pKi
Reference (Journal): Thalidomide mimics uridine binding to an aromatic cage in cereblon.
Published in: J Struct Biol

Ligand: dBRD9 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.5 pIC50
Reference (Journal): Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
Published in: Angew Chem Int Ed Engl

Ligand: dTAG-13 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.190000057220459 pIC50
Reference (Journal): The dTAG system for immediate and target-specific protein degradation.
Published in: Nat Chem Biol

Ligand: golcadomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Ligand: iberdomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.21999979019165 pIC50
Reference (Journal): A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Published in: J Med Chem

Ligand: lenalidomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: yes
Approval source: FDA (2005), EMA (2007)
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Published in: J Med Chem

Ligand: MD-222 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Published in: J Med Chem

Ligand: mezigdomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Published in: J Med Chem

Ligand: MG-277 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.510000228881836 pIC50
Reference (Journal): Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Published in: J Med Chem

Ligand: MS40 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 4.829999923706055 pKd
Reference (Journal): Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Published in: Oncogene

Ligand: NVP-DKY709 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.889999866485596 pIC50
Reference (Journal): Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.
Published in: Cell Chem Biol

Ligand: pomalidomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: yes
Approval source: FDA and EMA (2013)
Primary target: no
Median affinity: 5.920000076293945 pIC50
Reference (Journal): A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Published in: J Med Chem

Ligand: PTD10 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.96999979019165 pIC50
Reference (Journal): Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy
Published in: Journal of  Mediconal Chemistry

Ligand: SJ995973 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.
Published in: Angew Chem Int Ed Engl

Ligand: thalidomide (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: yes
Approval source: FDA (1998), EMA (2008)
Primary target: no
Median affinity: 8.069999694824219 pKd
Reference (Journal): Identification of a primary target of thalidomide teratogenicity.
Published in: Science

Ligand: TL12-186 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.
Published in: Cell Chem Biol

Ligand: TX-16 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pKi
Reference (Journal): Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
Published in: J Med Chem